Browsing by Author Ryden, Lars

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2013Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trialAnderson, Craig; Boehm, Michael; Gao, Peggy; Gerstein, H; Mann, Johannes F E; Ryden, Lars; Sleight, Peter; Teo, Koon; Yusuf, Salim; The George Institute for Global HealthDual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial, Journal of Hypertension, vol.31, 2, 2013,pp 414-421
2014Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trialNeal, Bruce; Buse, John B.; et al, .; Henry, Robert; Lincoff, A. Michael; Malmberg, Klas; Nicholls, Stephen; Ryden, Lars; Schwartz, Gregory; Tardif, Jean-Claude; Wedel, Hans; The George Institute for Global HealthEffect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial, JAMA, vol.311, 15, 2014,pp 1515-1525
2013Evaluation of the dual peroxisome proliferator-activated receptor a/y agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trialNeal, Bruce; Buse, John B.; et al, Various; Henry, Robert; Lincoff, A. Michael; Malmberg, Klas; Nicholls, Stephen; Ryden, Lars; Schwartz, Gregory; Tardif, Jean-Claude; Wedel, Hans; Weichert, Arlette; The George Institute for Global HealthEvaluation of the dual peroxisome proliferator-activated receptor a/y agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial, American Heart Journal, vol.166, 3, 2013,pp 429-434.e1